Loading…
Cellectis S.A. is projected to rise to $3.73 by 2027, a +25% move from its current price of $2.99. CLLS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $2.89 | $2.99 | $3.10 | +0.04% |
| Jul 14 | $2.85 | $2.99 | $3.14 | +0.09% |
| Jul 15 | $2.82 | $2.99 | $3.18 | +0.13% |
| Jul 16 | $2.79 | $3.00 | $3.21 | +0.18% |
| Jul 17 | $2.77 | $3.00 | $3.24 | +0.22% |
| Jul 18 | $2.75 | $3.00 | $3.26 | +0.27% |
| Jul 19 | $2.74 | $3.00 | $3.29 | +0.31% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.74 | $3.00 | $3.29 | +0.31% |
| Week 2 | $2.64 | $3.01 | $3.43 | +0.62% |
| Week 3 | $2.57 | $3.02 | $3.54 | +0.93% |
| Week 4 | $2.52 | $3.03 | $3.64 | +1.25% |
| Week 5 | $2.47 | $3.04 | $3.73 | +1.56% |
| Week 6 | $2.43 | $3.05 | $3.82 | +1.88% |
| Week 7 | $2.40 | $3.06 | $3.90 | +2.19% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cellectis S.A. is a clinical-stage biotechnological company that develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL).
It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma.
Cellectis S.A. (CLLS) is trading at $2.99, with a market cap of $301.09M and a rank of 3485. Symbol: CLLS.
A major floor 23.2% below — a decisive break under it would weaken the trend.
The nearest floor, 6.7% below — buyers have tended to step in here.
The nearest ceiling, 21.4% above — a clean break opens room to run.
A major ceiling 47.8% above — clearing it would confirm fresh momentum.
Key CLLS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CLLS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.15 | Sell | $3.10 | Sell |
| MA 10 | $3.08 | Sell | $3.09 | Sell |
| MA 20 | $3.03 | Sell | $3.10 | Sell |
| MA 50 | $3.38 | Sell | $3.29 | Sell |
| MA 100 | $3.54 | Sell | $3.47 | Sell |
| MA 200 | $3.81 | Sell | $3.44 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.33 | Neutral |
| Stoch RSI (14) | 55.26 | Neutral |
| CCI (20) | -21.36 | Neutral |
| Williams %R (14) | -60.78 | Info |
| MACD (12,26,9) | 0.04 | Buy |
| ROC (12) | 3.10 | Buy |
| Bollinger %B (20,2) | 0.43 | Neutral |
| Stochastic %K (14) | 39.22 | Neutral |
| TRIX (15) | -0.48 | Sell |
| Awesome (5,34) | -0.00 | Sell |
| Ultimate (7,14,28) | 48.44 | Neutral |
| Momentum (10) | 0.10 | Buy |
| Aroon Osc (25) | 24.00 | Buy |
| Hull MA (9) | 3.13 | Sell |
| ADX (14) | 17.81 | Neutral |
| ATR (14) | 0.11 | Info |
The 30-day picture shows NEUTRAL sentiment with RSI14 at 40. The price is trading below the SMA50 of $3.38 and the SMA200 of $3.81. Support is at $2.79 and resistance at $3.63. The 30-day range is $2.38 to $3.76 and the annualized volatility is 70%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.79 | $2.99 | $4.07 | 0% | Neutral | |
| $2.90 | $3.73 | $5.13 | +25% | Bullish | |
| $3.24 | $4.33 | $6.23 | +45% | Bullish | |
| $3.58 | $4.93 | $7.35 | +65% | Bullish | |
| $3.54 | $5.01 | $7.70 | +68% | Bullish | |
| $3.43 | $4.99 | $7.85 | +67% | Bullish | |
| $3.36 | $4.99 | $8.04 | +67% | Bullish | |
| $3.55 | $5.39 | $8.87 | +80% | Bullish | |
| $4.26 | $6.60 | $11.07 | +121% | Bullish | |
| $4.60 | $7.29 | $12.43 | +144% | Bullish | |
| $4.97 | $8.63 | $15.84 | +189% | Bullish | |
| $9.83 | $20.20 | $41.14 | +576% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.79 | $2.99 | $3.59 | +0.00% |
| August 2026 | $2.49 | $2.96 | $3.63 | -1.03% |
| September 2026 | $2.59 | $3.11 | $3.87 | +5.20% |
| October 2026 | $2.71 | $3.27 | $4.12 | +5.14% |
| November 2026 | $2.64 | $3.22 | $4.09 | -1.73% |
| December 2026 | $2.59 | $3.17 | $4.07 | -1.39% |
Click any year to see its month-by-month CLLS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The CLLS price prediction for 2026 points to an average of $2.99 (low $2.79, high $4.07) — a potential gain of 0% on today's $2.99. A consolidation phase looks the most probable path here.
In 2027, CLLS is projected to trade between $2.90 and $5.13, averaging $3.73 — a potential gain of +25% from today's $2.99. That is up +25% on the projected 2026 average. Momentum favours further upside here.
Cellectis S.A.'s 2028 outlook centres on $4.33, within a $3.24 to $6.23 range. That is up +16% on the projected 2027 average. That marks a +45% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, CLLS could reach as high as $7.35, with a base case around $4.93 and support toward $3.58 — roughly +65% from $2.99. Momentum favours further upside here.
Expect CLLS to range from $3.54 to $7.70 through 2030. The $5.01 average target implies a +68% move from current prices. That is up +2% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The CLLS price prediction for 2031 points to an average of $4.99 (low $3.43, high $7.85) — a potential gain of +67% on today's $2.99. Momentum favours further upside here.
In 2032, CLLS is projected to trade between $3.36 and $8.04, averaging $4.99 — a potential gain of +67% from today's $2.99. That is up 0% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Cellectis S.A.'s 2033 outlook centres on $5.39, within a $3.55 to $8.87 range. That is up +8% on the projected 2032 average. That marks a +80% change versus current levels. Momentum favours further upside here.
By 2034, CLLS could reach as high as $11.07, with a base case around $6.60 and support toward $4.26 — roughly +121% from $2.99. Buyers look set to stay in control over this stretch.
Expect CLLS to range from $4.60 to $12.43 through 2035. The $7.29 average target implies a +144% move from current prices. That is up +10% on the projected 2034 average. Momentum favours further upside here.
The CLLS price prediction for 2040 points to an average of $8.63 (low $4.97, high $15.84) — a potential gain of +189% on today's $2.99. Buyers look set to stay in control over this stretch.
In 2050, CLLS is projected to trade between $9.83 and $41.14, averaging $20.20 — a potential gain of +576% from today's $2.99. That is up +134% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in CLLS today (≈ 334.448161 CLLS) could be worth
$6,755.99
+$5,755.99 (+576%) by 2050 · US Dollar
Based on the average projected CLLS price of $20.2 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CLLSwould be worth at today's price.
$1,000 invested in CLLS on Jul 10, 2025 (≈ 606.060615 CLLS) would be worth
$1,812.12
+$812.12 (+81.2%) today · 1.81× · US Dollar
Based on a CLLS entry price of $1.65 vs. today's $2.99.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.3 | $906.06 | -9.4% |
| 1 month ago | $3.18 | $940.25 | -6.0% |
| 3 months ago | $3.59 | $832.87 | -16.7% |
| 6 months ago | $4.26 | $701.88 | -29.8% |
| 1 year ago | $1.65 | $1,812.12 | +81.2% |
| All time (5.0y) ago | $14.74 | $202.85 | -79.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CLLS forecast.
Our base-case forecast reaches $6.00 around 2034.
Implied market cap at $6.00: $436.19M
The multi-year outlook is bullish across the horizon, with the average price rising to $5.02 by 2030 (ROI 67.8) and to $20.21 by 2050 (ROI 576). The sentiment is BULLISH in years beyond 2026, with notable milestones including 2030 avg $5.02 and 2040 avg $8.63 (ROI 188.6). The 2050 max forecast reaches $41.16 (ROI value listed as 576).
These are estimates, not guarantees.
Tap a question to reveal the answer.
2030 avg price $5.02; min $3.54; max $7.70; ROI 67.8; sentiment BULLISH.
Forecast shows bullish sentiment from 2027 onward, with 2030 avg $5.02 and 2050 avg $20.21; ROI 67.8 in 2030 and 576 by 2050. These are estimates, not guarantees.
Yes—the 2050 max forecast is $41.16.
Current price $2.99; Market cap $301.09M.
30-day range low $2.38; high $3.76.
Cellectis S.A. Community Discussion
0Share your Cellectis S.A. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.